WHO Starts Bundibugyo Ebola Trial in Congo After 1,400 Cases and 438 Deaths

Q: Why is a known COVID-19 drug now a leading hope in Congo's latest Ebola outbreak?

Remdesivir is a leading hope because Congo’s outbreak is being driven by the Bundibugyo strain of Ebola, and there is no approved vaccine or strain-specific treatment for it. Health officials turned to remdesivir because it is a broad-spectrum antiviral with prior laboratory and outbreak-response evidence against filoviruses, the virus family that includes Ebola and Marburg. It is not proven yet for Bundibugyo Ebola, but experts judged it promising enough to move quickly into a clinical trial in Bunia, where patients are now being enrolled. Its biggest advantage is that it is already a known medicine. Remdesivir was widely used during COVID-19, giving regulators and researchers a large body of human safety data. In an emergency outbreak, that matters: a drug with an established safety profile can be tested faster than a completely new compound. The trial is also testing whether remdesivir works better alone or alongside MBP134, an experimental antibody therapy designed to work across multiple Ebola species. WHO-backed experts prioritized both candidates because Bundibugyo has been historically neglected and current options are limited to supportive care. The urgency is high. More than 1,400 cases and 438 deaths have been reported, and many deaths are occurring outside treatment centers. In that setting, a repurposed antiviral with known safety, available supply, and plausible activity against Ebola has become one of the most practical and immediate treatment hopes.

Q: Why might a 'less deadly' Ebola strain pose a greater threat of spreading across borders?

A less deadly Ebola strain can be more dangerous internationally because it may spread longer before it is recognized and contained. With the Bundibugyo strain, patients may have milder or less dramatic symptoms than in some deadlier Ebola outbreaks, including less extensive bleeding. That can delay diagnosis, especially in places where fever is easily mistaken for malaria or typhoid. If people do not realize they have Ebola, they may keep working, traveling, or crossing borders while infectious. A lower fatality rate can also mean infected people remain alive, mobile, and in contact with others for longer, creating more chances for transmission. In contrast, very severe Ebola cases often become incapacitated quickly, which can limit movement even if the virus is highly lethal. In this outbreak, those biological risks are amplified by local conditions. The virus is circulating in eastern Congo near the borders with Uganda and South Sudan, in an area shaped by mining traffic, displacement, refugee movement, insecurity, and weak health access. WHO and Africa CDC have warned that these factors make regional spread more likely. A confirmed case in Uganda has already shown that cross-border transmission is not theoretical. The danger, then, is not that Bundibugyo is harmless. It is that a somewhat less lethal strain, with no specific vaccine or approved treatment, can move more quietly through highly mobile populations before public health systems catch up.

3 articles · Updated · The Associated Press · Jul 5

The WHO-backed study enrolled its first patient in Bunia in early July, testing remdesivir, MBP134, and a combination of both against the Bundibugyo strain.
More than 1,400 people have been diagnosed and 438 have died in the still-growing outbreak, which has no specific approved treatment or vaccine.
The first phase is limited to confirmed Ebola patients at Bunia’s Evangelical Medical Centre, with survival tracked for 28 days; a second phase is planned for health workers and other high-risk contacts.
Nearly three out of four deaths are occurring outside health centers, while overcrowding, delayed care, insecurity and mistrust are slowing the response and limiting expansion of the trial.
Researchers expect the study to run three to six months, offering a rare source of hope in eastern Congo if access and safety conditions improve.

Sources

The Associated Press15h ago

WHO Launches Experimental Ebola Treatment Trial in Congo for Bundibugyo Virus

WBAL TV Baltimore8h ago

Residents in Congo cling to hope as a new Ebola treatment trial begins

Jacksonville Journal-Courier15h ago

Residents in eastern Congo cling to hope as a new Ebola treatment trial begins

13 Sources

With new treatments on trial, why are most Ebola victims still dying outside of hospitals?

Why is a known COVID-19 drug now a leading hope in Congo's latest Ebola outbreak?

Why might a 'less deadly' Ebola strain pose a greater threat of spreading across borders?

Bundibugyo Ebola Outbreak 2026: Rising Cases, High Death Toll, and the Global Response Gap

Overview

As of early July 2026, the Democratic Republic of the Congo is facing a rapidly growing Bundibugyo virus disease (BVD) outbreak, with 1,460 confirmed cases and 452 deaths. The outbreak is marked by sustained transmission and rising case numbers, highlighting the urgent need for strong public health action and scientific research. In response, the PARTNERS trial has been launched to test monoclonal antibodies and antiviral therapies, aiming to improve patient outcomes and reduce deaths. These efforts are crucial for controlling the outbreak and preparing for future threats from similar viruses.

...